StreetAlpha.app
Home › Stocks › KYNB

Kyntra Bio, Inc. (KYNB)

$2.05
▼ −33.87%
LAST CLOSE · NOV 17

Kyntra Bio develops cancer and anemia treatments, including a prostate cancer drug candidate and roxadustat, from San Francisco. It last closed at $2.05 on Nov 17, down 33.87% on the day. The average 12-month price target from 4 analysts is $22.75 (+1009.8% from the last close), with a high of $35.00 and a low of $8.00. Analyst consensus is Strong Buy, based on the latest ratings from 4 firms (4 buy, 0 hold, 0 sell).

AI Auto Pilots
Is KYNB in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$5.3M
−36.1% vs a year ago
Net income
−$17.3M
−108.0% vs a year ago
EPS (diluted)
−$4.29
−108.0% vs a year ago
Free cash flow
−$48.5M
−913.7% margin
Valuation
Market cap
$8.3M
4.0M shares
P/E
–
No P/E while losing money
Price to sales
1.6
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$9.9M
At Sep 30
Shareholder equity
−$29.2M
Shares outstanding
4.0M
At Oct 13
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $235.3M$235.3MFY2021FY2022: $140.7M$140.7MFY2022FY2023: $46.8M$46.8MFY2023FY2024: $29.6M$29.6MFY2024FY2025: $6.4M$6.4MFY2025

From KYNB's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 16). Last 12 months adds up the four latest quarters.

Last report
Nov 16
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 4 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
4firms
4 Buy0 Hold0 Sell
Each firm's latest rating on KYNB in the past 90 days
Average 12-month target
$22.75
▲ 1009.8% upside

Based on 4 analysts who set a price target on KYNB in the past 90 days. The average target is $22.75, with a high of $35.00 and a low of $8.00, compared with the last close of $2.05.

Low $8.00Avg $22.75High $35.00
Blue marker: last close $2.05
Highest target$35.00
Average target$22.75
Lowest target$8.00
Latest rating changes
Lake StreetTarget lowered
Nov 17Buy$41 → $8
OppenheimerTarget lowered
Nov 17Buy$35 → $30
HC Wainwright & Co.Target lowered
Nov 17Buy$43 → $18
Maxim GroupInitiated
Oct 13Buy$35
Lake StreetInitiated
Sep 17Buy$41
DateFirmActionRatingPrice target
Nov 17Lake StreetTarget loweredBuy$41 → $8
Nov 17OppenheimerTarget loweredBuy$35 → $30
Nov 17HC Wainwright & Co.Target loweredBuy$43 → $18
Oct 13Maxim GroupInitiatedBuy$35
Sep 17Lake StreetInitiatedBuy$41
Loading…

Technical Analysis

KYNB · as of the Nov 17 close · updated after every close
Downtrend, oversold

The stock is 99% below its 20 day and 174% below its 50 day average. It is 232% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 14), oversold. The nearest support is the 52 week low at $2.00, and the nearest resistance the Pivot at $2.10.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 19.1%/day
Key levels
$10.4752 week high+410.7%
$6.80200 day average+231.7%
$6.50100 day average+217.1%
$5.6150 day average+173.7%
$4.85Swing high (Oct 29)+136.6%
$4.0720 day average+98.5%
$2.19Pivot R1+6.8%
$2.10Pivot+2.4%
$2.05Last close
$2.0052 week low−2.4%
$1.95Pivot S1−4.9%
Indicators
RSI (14)14.15Oversold below 30Oversold
MACD-0.76Below its signal lineBearish
Stochastic2.0Near the bottom of its rangeOversold
ADX (14)62.2Strong downtrend
Williams %R-98.3Oversold below −80, overbought above −20Oversold
CCI (20)-233.4Oversold below −100, overbought above 100Oversold
Rate of change−52.4%Change over 10 sessionsBearish
ATR (14)$0.39Typical daily range, 19.1% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for KYNB

What happened before

See how KYNB did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow KYNB usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How KYNB has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2014.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in KYNB in the last 90 days.

Loading…

See today’s whale options flow across the market →

KYNB Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲11 buying vs 6 selling
  • ▲Held by funds +1.6 pts
  • ▲Funds holding +7
  • ▲Superinvestors: 2 added, 0 cut
  • ●Put/call not meaningful
Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding3528+25.0%
In funds' top 1000–
Held by funds26.2%24.7%+1.6 pts
New / increased7 / 41 / 5+83.3%
Reduced / sold out6 / 07 / 5−50.0%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See KYNB institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether KYNB is in one of them and how their past KYNB trades turned out.

KYNB in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered KYNB in an article yet. Here's the latest on the wider market.

About Kyntra Bio

Kyntra Bio is a biopharmaceutical company in San Francisco, California, that develops treatments for cancer and anemia. Its lead program, FG-3246, is a drug candidate for advanced prostate cancer, paired with FG-3180, an imaging agent that helps identify suitable patients. The company also holds rights to roxadustat, a treatment for anemia in patients with chronic kidney disease, and is developing it for a blood disorder called myelodysplastic syndromes.

Headquarters
San Francisco, CA